Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03031301 · ClinicalTrials.gov registry record · NA
A Study to Assess the Efficacy and Safety of the Vibrant Capsule Administered 5 Times Per Week
A NA study, sponsored by Vibrant.
- Completed
- Registry status
- NA
- Development phase
- 182
- Enrollment target
NCT03031301: Completed NA study, sponsored by Vibrant.
NCT03031301 is a NA study that has completed, run by Vibrant. The registered enrollment target is 182 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03031301, a NA study, has completed, sponsored by Vibrant.
- COMPLETED
- Registry status
- NA
- Development phase
- 182 participants
- Enrollment target
Study Summary
The study is a prospective, adaptive, multicenter, randomized, double-blind, Sham-controlled study, to evaluate the efficacy and safety of the Vibrant Capsule in relieving constipation in subjects with functional constipation. Two arms will be assessed: * Vibrant Capsule administered 5 times per week * Sham Capsule administered 5 times per week
Primary Outcome
CSBM1 success rate, defined as an increase from the run-in period of at least one weekly Complete Spontaneous Bowel Movement (CSBM) during at least 6 of the 8 weeks of treatment
Interventions
- DEVICE Vibrant capsule
- DEVICE Sham capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2018-07-30 |
| Phase | NA |
What the finished NCT03031301 record still lists
NCT03031301 is an interventional study that assigns participants to a tested intervention. The registered 182 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Vibrant capsule is the first listed.
NCT03031301 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03031301 about?
NCT03031301 is a clinical study titled "A Study to Assess the Efficacy and Safety of the Vibrant Capsule Administered 5 Times Per Week". The study is a prospective, adaptive, multicenter, randomized, double-blind, Sham-controlled study, to evaluate the efficacy and safety of the Vibrant Capsule in relieving constipation in subjects with functional constipation. Two arms will be assessed: * Vibrant Capsule administered 5 times per w...
What is the current status of trial NCT03031301?
This trial is currently completed. It is a NA study. The enrollment target is 182 participants. The study started on 2017-02-01. Estimated completion is 2018-07-30.
What interventions are being tested in trial NCT03031301?
The interventions under investigation include: Vibrant capsule (DEVICE), Sham capsule (DEVICE).
Who is sponsoring clinical trial NCT03031301?
This trial is sponsored by Vibrant, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03031301's enrollment target sits among peer trials
182 584th of 2000 higher than 1,415 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- NCT04323735 · 182 participants · Phase 2
Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters
- NCT05606731 · 182 participants · NA
Family Intervention to Prevent Childhood Obesity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI